<DOC>
	<DOC>NCT00846118</DOC>
	<brief_summary>The purpose of this study is to verify whether pitavastatin prevents from cardiovascular events and improves the mortality in chronic hemodialysis patients with hypercholesteremia.</brief_summary>
	<brief_title>Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis (DIALYSIS)</brief_title>
	<detailed_description>It was already proved by the clinical trials that statins prevent from death and cardiovascular events. However, the efficacy of statins in patients with chronic hemodialysis has not been proved yet.</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>patients under hemodialysis patients with hypercholesterolemia as defined by any of following parameters: LDLC ≧ 100 mg / dL TC ≧ 180 mg / dL patients required cholesterollowering treatment by investigators. patients aged 2075 years patients with written consent by their own volition after being provided sufficient explanation for the participation into this clinical trial patients taking statins or fibrates patients enrolled to the other trials using contraindication drugs of pitavastatin patients who had acute myocardial infarction within six months before the day of the agreement acquisition patients scheduled PCI and CABG within six months after the day of the agreement acquisition Patients who had diagnosis or doubt of malignant tumor patients corresponded to "Contraindications" of pitavastatin Familial hypercholesterolemia patients patients judged ineligible by investigators</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Pitavastatin</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Mortality</keyword>
	<keyword>Cardiovascular disease</keyword>
</DOC>